Rituximab in ANCA-Associated Vasculitis

被引：43
|
作者：
Hassan, Romina I. [1 ]
Gaffo, Angelo L. [2 ,3 ]
机构：
[1] JM Ramos Mejia Hosp, Div Rheumatol, 609 Gen Urquiza St, RA-1221 Buenos Aires, DF, Argentina
[2] Birmingham VA Med Ctr, 700 19th St S, Birmingham, AL 35233 USA
[3] Univ Alabama Birmingham, Div Rheumatol & Clin Immunol, 1825 Univ Blvd,SHEL 306, Birmingham, AL 35294 USA
来源：
CURRENT RHEUMATOLOGY REPORTS | 2017年 / 19卷 / 02期
关键词：
Rituximab; Vasculitis; ANCA; Granulomatosis with polyangiitis (GPA); Microscopic polyangiitis (MPA); Eosinophilicgranulomatosiswith polyangiitis (EGPA); WEGENERS-GRANULOMATOSIS; RANDOMIZED-TRIAL; PLASMA-EXCHANGE; CYCLOPHOSPHAMIDE; INDUCTION; REMISSION; THERAPY; MAINTENANCE; MANAGEMENT; RELAPSES;
D O I：
10.1007/s11926-017-0632-1
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Purpose of Review The purpose of this review is to describe the efficacy and safety of rituximab (RTX) as a remission induction and maintenance therapy in ANCA-associated vasculitis (AAV). Recent Findings A PubMed search was carried out to track down articles published between February 2006 and February 2016. Randomized controlled trials (RCTs) that encompassed patients with AAV were included. The American College of Rheumatology (ACR) and the European League against Rheumatism (EULAR) 2014-2015 online abstracts were also reviewed whether they were RTCs or not. Ten PubMed RCTs were analyzed along with eight ACR and four EULAR abstracts. RTX was not inferior to cyclophosphamide (CYC) for remission induction in AAV; it was superior to CYC in patients with relapsing disease and superior for remission maintenance in comparison with azathioprine (AZA). Summary Rituximab is a therapeutic option to induce and maintain remission in patients with AAV.
引用
收藏
页数：8
相关论文
共 50 条
  • [1] ANCA-associated vasculitis
    Yates, Max
    Watts, Richard
    CLINICAL MEDICINE, 2017, 17 (01) : 60 - 64
  • [2] Rituximab to treat ANCA-associated vasculitis
    Guillevin, L.
    Mahr, A.
    REVUE DE MEDECINE INTERNE, 2011, 32 (10): : 591 - 593
  • [3] Rituximab in ANCA-associated vasculitis: a revolution?
    Tervaert, Jan Willem Cohen
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2011, 26 (10) : 3077 - 3079
  • [4] ANCA-ASSOCIATED VASCULITIS
    Vandergheynst, F.
    ACTA CLINICA BELGICA, 2013, 68 (06) : 406 - 410
  • [5] Rituximab versus Cyclophosphamide for ANCA-Associated Vasculitis.
    Stone, John H.
    Merkel, Peter A.
    Spiera, Robert
    Seo, Philip
    Langford, Carol A.
    Hoffman, Gary S.
    Kallenberg, Cees G. M.
    Clair, E. William St.
    Turkiewicz, Anthony
    Tchao, Nadia K.
    Webber, Lisa
    Ding, Linna
    Sejismundo, Lourdes P.
    Mieras, Kathleen
    Weitzenkamp, David
    Ikle, David
    Seyfert-Margolis, Vicki
    Mueller, Mark
    Brunetta, Paul
    Allen, Nancy B.
    Fervenza, Fernando C.
    Geetha, Duvuru
    Keogh, Karina A.
    Kissin, Eugene Y.
    Monach, Paul A.
    Peikert, Tobias
    Stegeman, Coen
    Ytterberg, Steven R.
    Specks, Ulrich
    NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (03) : 221 - 232
  • [6] Renal Involvement in ANCA-associated vasculitis
    Kronbichler, Andreas
    Windpessl, Martin
    AKTUELLE RHEUMATOLOGIE, 2020, 45 (02) : 141 - 149
  • [7] Rituximab treatment of ANCA-associated vasculitis
    Raffray, Loic
    Guillevin, Loic
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2020, 20 (08) : 899 - 910
  • [8] Induction treatment of ANCA-associated vasculitis with a single dose of rituximab
    Turner-Stokes, Tabitha
    Sandhu, Eleanor
    Pepper, Ruth J.
    Stolagiewicz, Natalie E.
    Ashley, Caroline
    Dinneen, Deirdre
    Howie, Alexander J.
    Salama, Alan D.
    Burns, Aine
    Little, Mark A.
    RHEUMATOLOGY, 2014, 53 (08) : 1395 - 1403
  • [9] ANCA-Associated Vasculitis
    Sharma, Purva
    Zonozi, Reza
    Geetha, Duvuru
    ADVANCES IN KIDNEY DISEASE AND HEALTH, 2024, 31 (03): : 194 - 205
  • [10] Rituximab in ANCA-Associated Vasculitis
    Romina I. Hassan
    Angelo L. Gaffo
    Current Rheumatology Reports, 2017, 19
12345